关键词:局部晚期乳腺癌,新辅助治疗,周疗,化疗副反应

Abstract:Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy with paclitaxel administered weekly combined with epirubincin and cyclophosphamide regimen in advanced breast cancer. Methods: From October 1, 2017 to September 30, 2019, 76 patients with advanced breast cancer diagnosed after pathological examination were admitted to the Department of Nail Surgery, Chengwu County People's Hospital, Shandong Province, and paclitaxel was administered intravenously at. 80 mg/m²(7 d/time), epirubicin 600 mg/m²(1 d/time) and cyclophosphamide 500 mg/m²(1 d/time) in the chemotherapy after admission with 21 days as a cycle. Surgery was performed after 3 cycles of neoadjuvant chemotherapy, and radiation therapy was routinely performed in accordance with the NCCN guidelines. According to the solid tumor efficacy evaluation standard (RECIST1.1), the disease progression and adverse reactions of the patients were evaluated according to the WHO standard anti-cancer drug adverse reactions. Results: The completion rate of weekly treatment mode was 86.1%, including 32 patients with complete response (42.1%), 36 patients with progressive disease (47.4%), 7 patients with stable disease (9.2%),one patient with progressive disease(1.3%). During the treatment period, no congestive heart failure occurred in the entire group of patients, and related adverse reactions were observed from 5 aspects including hematological toxicity, nausea and vomiting levels, fatigue, oral inflammation and diarrhea, although most patients had different types of adverse reactions, but all levels of the status were less than those reported in other literatures, and grade Ⅳ nausea and vomiting did not appear. Conclusion: Retrospective analysis of neoadjuvant chemotherapy using epirubicin and cyclophosphamide combined with paclitaxel week treatment is beneficial to the prognosis of patients with advanced breast cancer, and patients tolerate adverse reactions during preoperative chemotherapy.

Key words:locally advanced breast cancer,neoadjuvant therapy,weekly therapy,side effects of chemotherapy